港股異動 | 嘉和生物-B(6998.HK)逆勢漲超4% GB492 I/IIa期臨牀試驗於中國完成首例患者給藥
格隆匯9月20日丨嘉和生物-B(6998.HK)現報10.64港元,逆勢漲4.31%,最新市值53億港元。嘉和生物上週四(16日)午間宣佈,GB492(干擾素基因刺激因子Stimulatorof interferon genes,STING激動劑)的I/IIa期臨牀試驗已於中國完成首例患者給藥。公吿稱,GB492是癌細胞固有免疫感知的主要介導體,由集團於2020年6月向ImmuneSensorTherapeutic獲得獨家許可協議。STING激動劑,作為一種免疫刺激療法,將進一步增加癌症患者對免疫檢查點抑制劑的反應。多項研究顯示,STING激動劑與其他免疫檢查點抑制劑(ICI)聯合使用可激活cGAS-STING信號通路,顯著增強腫瘤免疫週期的療效,將成為一種潛在的創新療法。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.